-
Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development
•
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector. Proceeds…
-
Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced a strategic partnership aimed at the joint development of innovative adjuvant vaccine technologies. The collaborative project, headquartered in Shanghai, will see Recbio contribute its independently developed new adjuvant based on their proprietary adjuvant technology platform.…
-
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a strategic licensing and partnership agreement with Saudi Arabian pharmaceutical firm SPIMACO. The agreement pertains to Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine, REC603. Under the terms of the deal, SPIMACO will secure exclusive rights to…
-
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results from the first-in-human (FIH) study for its novel adjuvanted recombinant shingles vaccine, REC610, which is being conducted in the Philippines. The study uses GlaxoSmithKline’s Shingrix (recombinant zoster vaccine; RZV), a major UK pharmaceutical company’s shingles…
-
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
•
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development cooperation agreement with Yikang Biological (Suzhou) Co., Ltd to develop a recombinant respiratory syncytial virus (RSV) vaccine aimed at preventing RSV-induced respiratory diseases. Under the terms of the agreement, Yikang will contribute its self-designed RSV…
-
Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA
•
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial filing for REC610, a novel adjuvanted recombinant shingles vaccine, for review. Phase I Clinical Trial Design and ObjectivesThe Phase I clinical trial is a randomized, double-blind, and GSK…
-
Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has received Emergency Use Authorization (EUA) from Mongolia for its ReCOV, a recombinant COVID-19 vaccine co-developed by the Chinese Academy of Sciences. This authorization marks a significant milestone in the global distribution and accessibility of the…
-
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
•
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of subject enrollment in a clinical study for its novel adjuvanted recombinant shingles vaccine, REC610. This milestone marks a significant step in the development of a vaccine designed to provide enhanced protection against shingles, particularly for…
-
Jiangsu Recbio’s Herpes Zoster Vaccine REC610 Gets Clinical Trial Approval in Philippines
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced receiving clinical trial approval for its new adjuvant recombinant herpes zoster vaccine, REC610, in the Philippines. The randomized, observer-blinded, Shingrix-positive controlled Phase I study is designed to assess the safety and immunogenicity of REC610 in healthy subjects aged…
-
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of a Phase II clinical study for its recombinant COVID-19 vaccine ReCOV in the Philippines as a sequential booster shot. The results showed that ReCOV as a sequential booster shot was superior to mRNA vaccine in…
-
Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial filing for its in-house developed neoadjuvant recombinant tetravalent human papillomavirus (HPV) vaccine has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development of Recbio’s vaccine…
-
Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment and dosing of all subjects in a Phase II clinical study for its ReCOV, a recombinant protein COVID-19 vaccine, with Pfizer’s mRNA vaccine Comirnaty as a control. The study, approved in the Philippines on August…
-
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject enrollment and first vaccination in an immuno-bridging study for its recombinant HPV 9-valent vaccine, REC603. The study targets younger-age groups and aims to compare the immunogenicity between REC603 and Gardasil 9. Meanwhile, follow-up on subjects…
-
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
•
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food and Drug Administration of the Philippines for its mRNA COVID-19 vaccine R520A. This approval marks a significant milestone in the global rollout of Recbio’s innovative vaccine targeting the Omicron variant. Vaccine InnovationR520A, developed by Wuhan…
